Adults with advanced melanoma invited to be in a research study using biomarkers to help guide safe immunotherapy discontinuation

UVA Tracking #
HSR200378
Principal Investigator
Elizabeth M Gaughan
Contact
Nicholas Baker
Contact Email
Contact Phone
434.982.6584
Official Trial Title
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have advanced melanoma. The purpose of this study is to find out if we can safely shorten the use of standard of care anti-PD1 therapy by using biomarkers seen on PET/CT imaging and tumor biopsy. Patients need to have received standard of care therapy for about 1 year prior to taking part in this study.

After the year of standard of care therapy you will have a PET/CT scan to assign you to one of 2 possible groups. If the results of the scan is negative you will come off the standard of care treatment. If the result is positive you will undergo a biopsy to determine if active cancer is still present. If there is no active cancer present on the biopsy, you will come off your standard of care treatment. If the biopsy is positive for active cancer, then you will continue on your standard of care treatment for 1 more year in order to complete 2 years total of anti-PD-1 therapy.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to
your or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04462406

Compensation

N/A